Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.60 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4272848 | 0.82 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3HSD11B1CYP2D6 | |
| SCHEMBL4272851 | 0.82 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3HSD11B1CYP2D6 | |
| SCHEMBL4282018 | 0.82 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3HSD11B1CYP2D6 | |
| Hydrochloric Acid SCHEMBL4271925 | 0.81 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3HSD11B1CYP2D6 | |
| SCHEMBL22319970 | 0.80 | GID4 (0.61) | SLC6A2SLC6A4SLC6A3GID4ADRA1A | |
| SCHEMBL4282005 | 0.79 | SLC6A2 (0.78) | SLC6A2SLC6A4SLC6A3HSD11B1CYP2D6 | |
| SCHEMBL4305585 | 0.78 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3CYP2D6MEN1 | |
| SCHEMBL4306070 | 0.75 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL4276678 | 0.74 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3HSD11B1CYP2D6 | |
| SCHEMBL15883779 | 0.74 | CYP19A1 (0.52) | SLC6A2SLC6A4SLC6A3HSD11B1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200253996-A1 | TCTP INHIBITING AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES, INFECTIOUS DISEASES, ALLERGIES, INFLAMMATIONS AND/OR ASTHMA | UNIVERSITE PARIS-SUD (FR) | 2020-08-13 | — | — | US | disclosed |
| US-20200253996-A1 | TCTP INHIBITING AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES, INFECTIOUS DISEASES, ALLERGIES, INFLAMMATIONS AND/OR ASTHMA | UNIVERSITE PARIS-SUD (FR) | 2020-08-13 | — | — | US | disclosed |
| WO-2019063955-A1 | AGENTS INHIBITING TCTP PROTEIN FOR THE TREATMENT OF PROLIFERATIVE DISEASES, INFECTIOUS DISEASES, ALLERGIES, INFLAMMATIONS AND/OR ASTHMA | UNIVERSITE PARIS-SUD (FR) | 2019-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200253996-A1 | TCTP INHIBITING AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES, INFECTIOUS DISEASES, ALLERGIES, INFLAMMATIONS AND/OR ASTHMA | NR3C1, TSLP, FPR3 | SLC6A2 3339/4885SLC6A4 2672/4885SLC6A3 2924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.